Iopamidol

Introduction Overview

Generic Name

iopamidol

Brand Name

Isovue-200
Isovue-250
Isovue-300
Isovue-370
Isovue-M-200
Isovue-M-300
Isovue-128
Iopamidol-370

Dosage Form

injectable solution (41%; 51%; 61%; 76%)
intrathecal solution (41%; 61%)

Drug Class

Non-ionic iodinated contrast media

Pharmacokinetics

Absorption:
Iopamidol is administered parenterally, predominantly via intravenous or intra-arterial infusion, or intrathecal injection depending on the radiological procedure required. Absorption is not applicable in the traditional sense of oral drug administration, as iopamidol is injected directly into the vascular system or cerebrospinal fluid. Upon administration, iopamidol rapidly distributes within the intravascular compartment and extracellular spaces but does not bind significantly to plasma proteins, which facilitates its rapid equilibration across compartment boundaries. The onset of radiographic contrast is immediate due to direct administration.

Distribution:
Following administration, iopamidol exhibits extensive distribution within the extracellular fluid but does not penetrate intracellular compartments due to its physicochemical properties. The volume of distribution approximates that of extracellular water, roughly 0.25 L/kg body weight. There is negligible binding to plasma proteins, and iodine atoms confer radiopacity allowing visualization of vascular structures, organs, and tissues on CT and other imaging modalities. Iopamidol crosses the blood-brain barrier only when this barrier is disrupted or when administered intrathecally for myelography. Its distribution is influenced by renal function and blood flow to tissues, with rapid equilibria between plasma and interstitial fluids.

Metabolism:
Iopamidol is chemically stable and pharmacologically inert; it undergoes virtually no metabolism by hepatic enzymes or other systemic metabolic pathways. The compound remains unchanged in the body throughout its distribution and elimination phases. This lack of metabolism minimizes the risk of metabolite-related toxicity and drug interactions.

Elimination:
Iopamidol is primarily eliminated unchanged by the kidneys via glomerular filtration. The plasma clearance rate correlates closely with renal function, and in individuals with normal renal function the elimination half-life ranges from approximately 2 to 3 hours. Less than 1% is eliminated via feces or other routes. The drug’s elimination is significantly delayed in patients with renal impairment, necessitating precautions to avoid nephrotoxicity. Due to renal clearance, hydration before and after administration is critical to prevent contrast-induced nephropathy. Intravascular retention times are minimized by rapid renal excretion, which also limits systemic toxicity.

Dosage Forms

Available Dosage Forms:
- Injectable solution with iodine concentrations of 41%, 51%, 61%, and 76%. These concentrations correspond to varying iodine content tailored for different imaging techniques and diagnostic requirements.
- Intrathecal solution available in concentrations of 41% and 61%, formulated specifically for use in myelography and ventriculography.

Dosages for Adults and Adolescents:
- Dosing is highly individualized based on the type of radiologic procedure performed, patient weight, renal function, and desired imaging clarity.
- Typical doses range from 50 mL to 150 mL injections, infused intravenously or intra-arterially during angiography, computed tomography (CT) scans, or urography.
- For intrathecal routes in myelography, smaller volumes are used, generally between 5 to 15 mL, adjusted as per procedural protocols and diagnostic needs.

Specific Patient Populations:
- In older adults or patients with compromised renal function, lower doses or extended hydration protocols are employed to reduce nephrotoxic risks.
- In patients with known hypersensitivity to contrast media, premedication and dose adjustments may be warranted.
- Pediatric and geriatric dosing regimens require careful consideration, balancing diagnostic benefits with minimizing adverse effects.
- Caution is advised in pregnant women; use only when medically necessary due to potential fetal risks.

Mechanism Of Action

Iopamidol functions as a radiopaque contrast agent used in diagnostic imaging procedures to enhance the visualization of vascular structures, organs, and tissues. Its primary mechanism is based on the presence of iodine atoms in its molecular structure, which exhibit high atomic number and effective X-ray absorption capacity. When administered, iopamidol absorbs and attenuates X-rays, leading to increased contrast of blood vessels and tissues relative to surrounding structures on radiologic images.

At the molecular level, iopamidol is a non-ionic, water-soluble, tri-iodinated benzamide derivative. Its non-ionic nature reduces osmolality and minimizes protein binding, contributing to a lower incidence of adverse reactions compared to ionic contrast agents. Upon intravenous or intra-arterial injection, iopamidol circulates freely in the bloodstream and distributes into extracellular water without cellular uptake. This distribution allows opacification of vascular lumens, cardiac chambers, urinary tracts, and ventricles in the central nervous system during imaging.

Clinically, iopamidol's ability to sharply delineate anatomical structures facilitates accurate diagnosis of pathological conditions such as vessel stenosis, aneurysms, organ lesions, and tumors. Its use extends to CT enhancement, myelography via intrathecal administration, arteriography, and urography. Compared to similar iodinated contrast agents, iopamidol offers a favorable safety profile due to its non-ionic formula and intermediate osmolality, balancing effective imaging contrast with reduced toxicity.

Extensive clinical studies demonstrate that iopamidol’s radiopacity and physicochemical properties allow for high-quality imaging with minimal adverse reactions. Research supports its utility across multiple imaging modalities and patient populations, including those with mild renal insufficiency, provided adequate precautions are observed. The development of low-osmolality non-ionic agents like iopamidol represents a significant advancement in contrast media technology, improving diagnostic efficacy while enhancing patient safety.

Pharmacological Actions

Acts as a radiopaque contrast medium by absorbing X-rays due to its iodine content.
Enhances visualization of blood vessels, organs, and tissues during radiological procedures such as CT scans, arteriography, myelography, and urography.
Non-ionic nature reduces osmolality compared to ionic contrast agents, lowering the risk of adverse reactions.
Distributes rapidly in the extracellular fluid without binding to plasma proteins or penetrating cells.
Chemically stable and pharmacologically inert, with no metabolic transformation in the body.
Excreted primarily by renal filtration, with elimination correlating closely with kidney function.
Suitable for intravascular and intrathecal administration allowing diverse diagnostic uses.
Facilitates contrast enhancement in computed tomography by increasing the radiodensity of vascular and tissue structures.
Does not cross intact blood-brain barrier unless administered intrathecally or in case of barrier disruption.
Low potential for neurotoxicity when used within recommended dosage and administration protocols.
Reduces risk of nephrotoxicity through low osmolality formulation and requirement for adequate patient hydration.
Provides rapid onset of imaging contrast with immediate effect post-administration.
Compatible with other diagnostic agents for combined imaging procedures.
Minimal protein binding decreases risk of interactions with endogenous or exogenous compounds.
Demonstrated stability and efficacy across multiple iodinated contrast media formulations.

Therapeutic Or Clinical Uses

Contrast enhancement in computed tomography (CT) scans for improved visualization of organs and vasculature.
Diagnostic cerebral, peripheral, and coronary arteriography for evaluation of vascular diseases.
Myelography to assess spinal cord pathology via intrathecal injection.
Ventriculography and cisternography to visualize cerebrospinal fluid spaces.
Excretory urography for imaging the urinary tract including kidneys, ureters, and bladder.
Selective visceral arteriography for detailed assessment of abdominal organ blood supply.
Aortography for examination of the aorta and its branches.
Evaluation of coronary artery disease through coronary angiography and ventriculography.
Detection and delineation of tumors, aneurysms, stenosis, and vascular malformations.
Preoperative and postoperative imaging assessments in cardiovascular and neurological surgery.
Intravenous contrast for enhanced imaging during diagnostic and interventional radiological procedures.
Used as a diagnostic aid in patients suspected of stroke, blood clots, and vascular abnormalities.
Employed in pediatric and adult populations where appropriate diagnostic imaging is indicated.
Utilized in clinical settings requiring advanced imaging to confirm or rule out pathologies.
Applied in imaging scenarios where non-ionic, low-osmolality agents are preferred to minimize risks.

Side Or Adverse Effects

Acute allergic reactions including hives, itching, and erythema.
Serious hypersensitivity reactions such as anaphylaxis presenting with respiratory distress or facial swelling.
Delayed skin reactions including rash, fever, red or purple blistering skin lesions.
Cardiovascular effects such as chest pain and bradycardia (slow heart rate).
Respiratory symptoms including wheezing and difficulty breathing.
Neurological events including seizures (convulsions).
Thyroid dysfunction characterized by symptoms such as severe fatigue, dry skin, joint and muscle pain, hoarseness, cold intolerance, and weight gain.
Symptoms suggestive of heart attack including chest pressure radiating to jaw or shoulder, nausea, and sweating.
Signs of blood clots in the lung such as sudden chest pain, cough, shortness of breath, or hemoptysis (coughing up blood).
Stroke symptoms comprising sudden unilateral weakness, speech difficulty, visual disturbance, or severe headache.
Common minor reactions include hot flashes, flushing, burning sensations, nausea, and dizziness.
Potential nephrotoxicity particularly in patients with preexisting renal impairment or dehydration.
Injection site reactions including pain, burning sensation, and swelling around the intravenous needle.
Rare but serious multi-organ hypersensitivity reactions with flu-like symptoms and tissue swelling.
Reactions may be immediate or delayed, occurring 30 to 60 minutes after administration.

Precautions

Assess patient history for prior reactions to iodinated contrast agents to minimize hypersensitivity risk.
Monitor renal function closely before and after administration, particularly in patients with existing kidney disease.
Ensure adequate hydration before and after administration to reduce risk of contrast-induced nephropathy.
Use caution in patients with congestive heart failure to prevent fluid overload and related complications.
Avoid administration during active infections due to increased risk of adverse effects.
Evaluate thyroid function as iodine content may affect thyroid hormone synthesis and metabolism.
Screen for history of asthma, hay fever, or multiple allergies which predispose to contrast reactions.
Minimize dose and carefully monitor patients with seizure disorders or neurological diseases.
Consider risk-benefit ratio in pregnant and breastfeeding women; use only if clearly indicated.
Avoid unnecessary use in patients with sickle cell anemia due to potential exacerbation of vaso-occlusive crises.
Inform patients about possible delayed reactions and instruct them to report symptoms promptly.
Premedication strategies may be necessary in patients with past mild to moderate reactions to contrast.
Monitor for signs of dehydration post-procedure, especially in elderly patients.
Avoid concomitant use with nephrotoxic medications without appropriate monitoring.
Adjust dosing and imaging protocols in patients with multiple myeloma or bone cancers.

Warnings

Contraindicated in patients with any type of active infection.
Risk of severe allergic or anaphylactoid reactions including life-threatening anaphylaxis.
Potential for serious delayed hypersensitivity reactions affecting multiple organs.
May cause nephrotoxicity, particularly in patients with impaired renal function or inadequate hydration.
Can interfere with subsequent medical tests for up to 16 days after administration.
Risk of thyroid dysfunction, including hypothyroidism or hyperthyroidism, due to iodine load.
Use cautiously in patients with cardiovascular disease due to risk of arrhythmias or ischemia.
Seizure risk heightened in patients with preexisting seizure disorders.
Potential for fluid overload and electrolyte imbalance in patients susceptible to heart failure.
Risk of blood clots or embolic events particularly in patients with vascular disease history.
Monitor for signs of stroke or pulmonary embolism after administration.
Avoid dehydration during and after use, as vomiting or diarrhea may worsen renal toxicity.
Patients should be observed post-injection for at least 30 to 60 minutes to detect delayed adverse reactions.
Inform medical personnel of recent iopamidol use prior to further imaging or interventions.
Extremely rare but serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.

Contraindication

Known hypersensitivity to iopamidol or other iodinated contrast agents.
Active infections contraindicate use due to increased risk of adverse events.
Severe renal impairment where use may precipitate contrast-induced nephropathy.
Decompensated heart failure where volume overload risk outweighs imaging benefits.
Previous severe anaphylactic reaction to any iodinated contrast media.
Patients with thyroid storm or uncontrolled hyperthyroidism.
Pregnancy only if the diagnostic information is critical and cannot be obtained by other methods.
Concomitant use during metformin therapy without appropriate renal function monitoring.
Severe hepatic dysfunction if combined with renal impairment increases toxicity risk.
Patients exhibiting severe dehydration until adequately rehydrated.
Contrast use contraindicated if intrathecal administration is not indicated or improperly performed.
Known pheochromocytoma without adequate medical control due to risk of hypertensive crisis.
Patients with multiple myeloma and significant renal dysfunction require caution or avoidance.
Infants and neonates only if absolutely necessary, due to limited safety data.
Concomitant use with other nephrotoxic drugs without monitoring.

Drug Interactions

Metformin and metformin-containing diabetes medications (e.g., Glucophage, Glucovance) - risk of lactic acidosis if renal function is compromised post-contrast administration.
Other nephrotoxic agents including aminoglycosides, amphotericin B, and NSAIDs may increase risk of kidney damage when used concomitantly.
Diuretics may exacerbate dehydration and renal impairment risk during contrast use.
Lithium may have altered renal clearance during iopamidol administration.
Beta-blockers and ACE inhibitors may complicate management of potential contrast reactions.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate nephrotoxicity.
Medications affecting thyroid function may interact with iodine load from iopamidol.
Antihypertensive medications may require adjustment post-contrast due to volume shifts.
Potential interaction with anticoagulants, increasing bleeding risk during invasive procedures.
Concomitant use with other iodinated contrast media can increase cumulative toxicity.
Drugs metabolized by renal clearance may have altered pharmacokinetics in setting of contrast-induced nephropathy.
Corticosteroids may be used prophylactically to reduce hypersensitivity reactions when drug interactions pose risk.
Herbal supplements with nephrotoxic potential should be disclosed and managed accordingly.
Radiopharmaceuticals and imaging agents may have interference or altered imaging characteristics when combined.
Immunosuppressive agents may increase susceptibility to adverse reactions.

Preparations Of The Drug

Isovue-200 Injectable Solution (41% iodine concentration) suitable for general vascular and CT imaging.
Isovue-250 Injectable Solution (51% iodine concentration) providing intermediate iodine content for enhanced imaging clarity.
Isovue-300 Injectable Solution (61% iodine concentration), commonly used for angiographic studies requiring higher contrast.
Isovue-370 Injectable Solution (76% iodine concentration) reserved for high-resolution imaging needs such as cardiac ventriculography.
Isovue-M-200 and Isovue-M-300 Intrathecal Solutions (41% and 61%) formulated specifically for myelography and neuro-radiologic procedures.
Iopamidol-370 Injectable Solution - high iodine concentration preparation for detailed vascular studies.
Sterile, preservative-free formulations prepared under aseptic conditions to minimize infection risk.
Solutions are iso-osmolar or low-osmolar relative to older ionic contrast agents, enhancing patient tolerability.
Packaged in single-use vials or prefilled syringes to ensure dosing accuracy and maintain sterility.
Supplied in varying volumes to accommodate diverse procedural requirements from small intrathecal doses to large intra-arterial infusions.
Ready-to-use formulations that do not require dilution prior to administration, unless specified by protocol.
Each preparation includes labeling specifying iodine concentration, intended use, and safety precautions.
Manufactured to meet strict pharmacopoeial standards governing iodinated contrast media quality and purity.
Compatible with standard intravenous catheters and radiographic equipment for ease of administration.
Includes detailed prescribing information outlining indications, preparation instructions, and adverse event management.